Nasopharyngeal Carcinoma

Patients with nasopharyngeal carcinoma who received radiotherapy in the morning survived longer than those who underwent radiotherapy later in the day, according to study results.

Patients with locoregionally advanced nasopharyngeal carcinoma may benefit from radiotherapy alone, result from a randomized phase 3 study suggest.

The FDA approved toripalimab-tpzi for two indications as treatment for nasopharyngeal carcinoma, making it the first approved therapy for this malignancy.

CHICAGO — When added to induction chemotherapy and concurrent chemoradiotherapy, sintilimab conferred a 41% reduction in risk for disease recurrence or death among patients with high-risk locoregionally advanced nasopharyngeal carcinoma.

Induction chemotherapy with paclitaxel, cisplatin and capecitabine vs. cisplatin and fluorouracil improved failure-free survival among patients with advanced nasopharyngeal carcinoma, according to a study published in JAMA Oncology.

CHICAGO — Intensity-modulated radiotherapy conferred disease control and survival outcomes comparable to concurrent chemoradiotherapy but with less toxicity among patients with low-risk nasopharyngeal carcinoma, according to study results.

Capecitabine maintenance therapy significantly prolonged PFS among patients with newly diagnosed metastatic nasopharyngeal carcinoma who achieved disease control after capecitabine-containing induction chemotherapy, according to a study.

Rare Disease Day is Feb. 28.

The FDA granted breakthrough therapy designation to toripalimab in combination with chemotherapy for first-line treatment of recurrent or metastatic nasopharyngeal carcinoma, according to the agent’s manufacturer.

Adding toripalimab to gemcitabine-cisplatin chemotherapy significantly improved PFS and overall response rates and induced longer-lasting responses than chemotherapy alone as first-line therapy for advanced nasopharyngeal carcinoma.